Erenumab was approved by FDA in 2018 for: (A) Phenylketonuria, (B) Migraine, (C) Hypeension, (D) Glycogen storage disorders
Answer is B. Erenumab belongs to a new class of drugs known as selective calcitonin gene-related peptide (CGRP) antagonists, which are used for the treatment of acute migraine attacks.